(Information sent by the signatory company)
– NeoChord, Inc. appoints new CEO to lead commercialization efforts and study a new first-line therapy for mitral valve regurgitation
MINNEAPOLIS, Feb. 22, 2024/PRNewswire/ — NeoChord is a privately held medical technology company and a global leader in providing artificial chords to the beating heart for the treatment of mitral valve regurgitation. The company named Todd Berg as CEO to oversee clinical and commercial programs for transseptal and transapical repair of damaged mitral valve chordae that cause regurgitation.
Berg most recently served as CEO of Metavention, an intravascular denervation company that pioneered multi-organ denervation for the treatment of type 2 diabetes and hypertension. Previously, Berg was CEO of Torax Medical, which developed magnetic augmentation for the treatment of gastroesophageal reflux disease and was acquired by Ethicon, a division of Johnson
“One of the most important clinical gaps in heart structural innovation is providing patients with a treatment option to address mitral regurgitation before the disease progresses to stages where the heart becomes damaged. The opportunity to develop a therapy first-line treatment for mitral valve disease, resolving regurgitation early in the disease state, is incredibly compelling,” Berg explained.
Casey Tansey, general partner at U.S. Venture Partners, commented: “NeoChord’s long-term commitment to advancing the treatment of mitral regurgitation, since its founding at the Mayo Clinic, has established a solid foundation of clinical success and commitment to patient benefit. We are confident Berg and its new management team will expand this foundation into a new era of innovation by adding a minimally invasive transseptal approach to complement the company’s commercially successful transapical repair products.”
About Mitral Valve Regurgitation
Degenerative mitral valve disease is the third most common cardiovascular disease in both Europe and the United States. The prevalence of severe mitral valve regurgitation is estimated at 3 to 5 million patients, but less than 3% of these patients receive adequate treatment due to the invasiveness of open heart surgery. Degenerative mitral valve disease is the most common cause of mitral regurgitation with a primary etiology of leaflet prolapse due to an elongated or broken chordal support. The mitral valve chords are the main physiological support mechanism that prevents leaflet prolapse that causes regurgitation. The ideal therapy for patients with degenerative mitral valve insufficiency is early intervention to restore normal function of the chordae. Minimally invasive administration of neochords allows for more physiologic restoration of regurgitation without limiting any future valvular treatment options.
About NeoChord
NeoChord is the global leader in beating heart mitral valve chord repair with a portfolio of commercial and clinical product technologies. The DS1000 transapical (TA) chordae repair system is commercially available in Europe and has been used to place more than 5,000 successful neocordas in more than 2,000 patients. NeXus is a transseptal chord (TS) repair system that incorporates the same patented suture-based anchoring elements proven in the DS1000 experience and is currently in clinical feasibility trials.
For more information, visit www.neochord.com
Logo – https://mma.prnewswire.com/media/2344969/NeoChord_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/neochord-inc-nombra-un-nuevo-consejero-delegado-para-liderar-los-esfuerzos-de-comercializacion-302068818.html
